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Abstract 
Thyroid hormone (TH) signaling plays critical roles in the differentiation, growth, metabolism, and physiological func‑
tion of all organs or tissues, including heart and skeletal muscle. Due to the significant progress in our understanding 
of the molecular mechanisms that underlie TH action, it’s widely accepted that TH signaling is regulated at multiple 
levels. A growing number of discoveries suggest that microRNAs (miRNAs) act as fine‑tune regulators of gene expres‑
sion and adds sophisticated regulatory tiers to signaling pathways. Recently, some pioneering studies in cardiac and 
skeletal muscle demonstrating the interplay between miRNAs and TH signaling suggest that miRNAs might mediate 
and/or modulate TH signaling. This review presents recent advances involving the crosstalk between miRNAs and 
TH signaling and current evidence showing the importance of miRNA in TH signaling with particular emphasis on 
the study of muscle‑specific miRNAs (myomiRs) in cardiac and skeletal muscle. Although the research of the recipro‑
cal regulation of miRNAs and TH signaling is only at the beginning stage, it has already contributed to our current 
understanding of both TH action and miRNA biology. We also encourage further investigations to address the relative 
contributions of miRNAs in TH signaling under physiological and pathological conditions and how a group of miRNAs 
are coordinated to integrate into the complex hierarchical regulatory network of TH.
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Background
Thyroid hormone
Thyroid, the largest endocrine organ of human body, syn-
thesizes and secretes thyroid hormones (THs), includ-
ing triiodothyronine (T3) and thyroxine (T4), which act 
upon nearly every cell in the body. The production of TH 
by thyroid is tightly controlled by a negative feedback 
loop of hypothalamus–pituitary–thyroid axis [1–3]. T4 is 
the most abundant TH in the blood, which is converted 
into T3, the biologically active form of TH, by iodothyro-
nine deiodinase selenoenzymes in cells. The physiologi-
cal roles of TH have been extensively studied for more 
than a century. It is known that TH plays critical roles in 
growth, differentiation, development, and metabolism [2, 
4–6]. One of the most important questions in the field of 
TH action is how the diverse biological activities of TH 
are achieved.
Thyroid hormone receptor
The action of TH is mediated mainly through its bind-
ing to thyroid hormone receptor (TR), which is a ligand-
dependent transcription factor that belongs to the 
nuclear receptor superfamily [3]. TR binds to the thyroid 
hormone response element (TRE) within the promoter of 
target genes as either homodimers or heterodimers with 
retinoid X receptor (RXR). The transcription mediated 
by TR involves the T3 binding-induced conformational 
change of TR and the dynamic interplay with nuclear 
receptor coregulators [1, 3]. In general, unliganded TR 
interacts with corepressors to inhibit target gene tran-
scription, while, in the presence of T3, T3-bound TR 
recruits coactivators to promote the transcription [1]. In 
contrast, the mechanisms underlying T3-mediated tran-
scriptional repression are still poorly understood. TRs 
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are encoded by two genes, TRα and TRβ, which gener-
ate multiple isoforms through alternative splicing or pro-
moter. Among these TRs, only TRα1 and TRβ1-3 have 
the capacity to bind T3 [7]. TRα and TRβ genes are dif-
ferentially expressed during development and in adult 
tissues, which provides an additional means to modulate 
the TH actions in a temporal and spatial manner [3, 7]. In 
addition, TR is subject to posttranslational modification 
by phosphorylation and sumoylation, which also contrib-
ute to the modulation of TR activity [8, 9].
Thyroid hormone and its action on cardiac 
and skeletal muscle
Effects of thyroid hormone on heart
The close relationship between thyroid and heart was 
noted in the earliest descriptions of hyperthyroidism. The 
impact of thyrotoxicosis on cardiovascular system was 
first described in 1785 by Caleb Parry, a British physi-
cian who noticed an association between a swelling neck 
and heart failure [10]. In general, the profound effects of 
TH on cardiac function include enhancing overall total 
protein synthesis, lowering systemic vascular resistance, 
increasing blood volume, and modulating inotropic and 
chronotropic response [11]. The combination of these 
effects on both the circulation and the heart itself results 
in an increase in cardiac output. Hyperthyroid patients 
exhibit a high cardiac output state, whereas hypothyroid 
patients display low cardiac output, decreased stroke vol-
ume, decreased vascular volume, and increased systemic 
vascular resistance [11, 12]. It is well accepted that both 
the direct regulation of target genes by TH and the indi-
rect effects of TH on hemodynamics contribute to these 
changes [11–13].
Myosin is one of the key components of contractile 
apparatus, where chemical energy of adenosine triphos-
phate (ATP) is converted to mechanical work [14]. There 
are three isoenzymes of ventricular myosin in heart, 
which differ in their myosin heavy chain (MHC) α and 
β composition: myosin V1 (α/α), myosin V2 (α/β), and 
myosin V3 (β/β) [14]. Myosin V1 has the highest ATPase 
activity and V3 the lowest. Myosin V2 has an ATPase 
activity intermediate between V1 and V3. Thus, the ratio 
of the V1 to the V3 isoenzyme of myosin determines car-
diac contractility and correlates with cardiac muscle per-
formance as indicated by mechanical, myothermal, and 
biological analysis [14]. The relative amounts of the three 
isoforms (V1, V2, and V3) not only change with age, or 
stress (exercise or ventricular pressure overload), but also 
change under altered thyroid states (hypothyroidism or 
hyperthyroidism) [15].
It is known that TH has opposing effects on α-MHC 
and β-MHC gene expression [16, 17]. Putative TREs for 
both α-MHC and β-MHC genes have been reported in 
the promoter region of these two genes. The two TREs 
identified in the promoter of α-MHC are imperfect direct 
repeats, which are separated by four nucleotides [18, 19]. 
Regarding β-MHC, a putative negative TRE (nTRE) con-
taining a single half-site is found adjacent to the TATA 
box [20, 21]. The increase of α-MHC gene expression and 
the decrease of β-MHC gene expression by T3 result in 
an increase in myosin V1 levels and enhanced cardiac 
contractility [19]. In contrast, induction of a hypothy-
roid state increases myosin V3 composition, which leads 
to a decrease in velocity of fiber shortening [16, 19]. In 
addition, a surge in TH levels after birth also contributes 
to the developmental switch in the ventricles of rat, in 
which α-MHC mRNA increases shortly after birth and 
almost replaces β-MHC mRNA completely in a week 
[22]. Although the developmental pattern for MHC iso-
forms is different and the effect of T3 on α-MHC is small 
in higher mammals, a clinical study showed that T4 
replacement improved cardiac function of a hypothy-
roid patient, which was accompanied with a more than 
10-fold increase of α-MHC mRNA levels in the patient’s 
ventricles [23]. Therefore, due to its ability to control the 
expression of MHC isoforms, TH is a critical player in 
the regulation of cardiac function.
Changing concentrations of cytosolic Ca2+ in car-
diac myocytes controls each cycle of contraction and 
relaxation [24]. Cardiac sarcoplasmic reticulum calcium 
ATPase (SERCA2), which is an intracellular ion pump, 
plays a critical role in maintaining the intracellular Ca2+ 
homeostasis [25]. SERCA2 removes the Ca2+ from the 
cytosol and stores the Ca2+ in the sarcoplasmic reticu-
lum, which leads to diastolic relaxation [25]. The expres-
sion of SERCA2 was decreased in hypothyroid rats, while 
the levels of SERCA2 could be elevated by T3 treatment, 
suggesting that SERCA2 is positively regulated by TH 
[26, 27]. Thus, TH is able to relax the heart and enhance 
cardiac output by reducing the amount of cytosolic Ca2+ 
through increasing SERCA2 expression [26, 27]. For the 
time being, three TREs arranged as direct repeats (DRs) 
and inverted palindromes have been identified in the 
promoter region of SERCA2 gene [28]. Besides regulating 
SERCA2 expression, T3 can also shape heart function by 
targeting other ion channels such as voltage-gated potas-
sium (Kv) channel Kv1.5, Na+/K+-ATPase, and hyperpo-
larization activated cyclic nucleotide-gated channel [29, 
30]. In addition, TH may enhance the cardiac sensitivity 
to catecholamines through controlling the β-adrenergic 
receptor expression [31].
Recent findings from TR mutant mouse models sub-
stantiate the role of TH in the physiology of heart [32]. 
Introducing a dominant negative mutant TRβ into 
the heart of mice suppressed the mRNA expression of 
α-MHC and SERCA2, but upregulated the mRNA levels 
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of β-MHC, which led to prolonged cardiac muscle con-
traction and QRS interval [33]. Studies using TR isoform-
specific mouse models have elucidated that TRα and TRβ 
play differential roles in the regulation of heart rate [34]. 
Mice deficient in TRα showed decreased heart rate and 
prolonged QRS interval, whereas mice lacking TRβ had 
elevated heart rate, which was resistant to TH treatment. 
These findings suggest that TRα1 is more important for 
maintaining baseline heart rate, whereas TRβ may be 
only involved in TH-mediated stimulation of heart rate 
[34, 35]. Due to the beneficial effect of TH on cardiac 
function, T3 has been employed for heart surgery includ-
ing cardiac transplantation and cardiac bypass surgery.
Effects of thyroid hormone on skeletal muscle
Skeletal muscle is a major target organ of TH. Myopathic 
symptoms are very common among hyperthyroid or 
hypothyroid patients [36]. The effects of THs on mus-
cle contractility and metabolism have been extensively 
studied [5]. It is known that MyHC gene expression is 
controlled by TH [16, 37, 38]. Muscles of hypothyroid 
patients typically display a conversion from fast to slow 
fiber types, and a more efficient energy metabolism 
[39]. Hypothyroid patients have less type-II fibers in the 
muscle, as compared to euthyroid patients [39]. Inter-
estingly, hypothyroid females have higher proportion of 
type-II fibers than hypothyroid males; however, type-II 
fiber atrophy occurs only in hypothyroid female patients 
[40], suggesting there is a gender-dependent mechanism 
involved.
In general, experimental hyperthyroidism in rats using 
T3 could induce a reversible slow-to-fast MyHC iso-
form transition from I  →  IIa  →  IIx  →  IIb [41]. How-
ever, gender- and muscle-specific differences were always 
observed in the regulation of MyHC isoforms by T3 in 
rats. Normally, almost all myofibers in the soleus mus-
cle of rats expressed the slow MyHC isoform (type-I 
fibers) [38]. Four weeks of T3 treatment resulted in an 
increase of type-IIA fibers and a decrease of type-I fib-
ers [42]. After T3 treatment, compared to male rats, the 
soleus muscle of female rats expressed more type-I fib-
ers and less type-I/IIa and type-I/IIax fibers [39]. Moreo-
ver, the IIx content from the type-I/IIax fibers increased 
more in T3-treated male rats than that in female rats, 
while the upregulation of IIa content was greater in 
female rats than that in male rats [39]. In addition, it has 
been reported that T3 treatment induced IIx MyHC iso-
form expression only in the soleus muscle of male rats, 
whereas IIx expression could not be detected in female 
rats at any age [43].
In contrast to soleus muscles, extensor digitorum lon-
gus (EDL) muscles contain predominantly fast MyHC 
isoforms (IIa, IIx, and IIb) [44]. Increased levels of 
MyHC-IIa were observed in the EDL muscle of hypothy-
roid rat [45]. One study showed that long-term T3 treat-
ment reduced both MyHC-IIb and MyHC-IIa expression 
at mRNA and protein levels in the EDL muscle [46]. 
However, in another study, chronic hyperthyroidism 
increased MyHC-IIb mRNA expression without chang-
ing the protein levels in rat EDL muscle [47]. It has been 
reported that T3 treatment in euthyroid rats resulted in a 
transition from IIa to IIb fibers only in the EDL muscle of 
female rats, but not in that of male rats, further suggest-
ing there is a gender difference in fiber-type conversion 
[40]. These studies indicate that the effect of TH on mus-
cle contractibility, endurance, and the response to fatigue 
might differ between females and males, presumably as 
a result of a gender difference in the regulation of fiber-
type switch.
MicroRNAs biogenesis and functions
MicroRNAs (miRNAs), first identified in C. elegans in 
the early 1900s [48], are a group of highly conserved non-
coding RNAs and approximately 22 nucleotides in length 
[49]. miRNAs function primarily as negative regulators 
of gene expression at the post-transcriptional level [49, 
50]. miRNAs can be classified as intronic and intergenic 
based on their genomic location [49, 51]. In general, 
intronic miRNAs are located in the introns of protein 
coding genes and transcribed along with their host genes, 
while intergenic miRNAs have their own promoters and 
are transcribed as independent transcripts [49, 51].
miRNAs are usually transcribed by RNA polymerase 
II as primary miRNAs (pri-miRNAs) in the nucleus [52]. 
However, it also has been reported that a few miRNAs 
requires RNA polymerase III to generate pri-miRNAs 
[53]. After transcription, pri-miRNAs are then processed 
by microprocessor complex, which is composed of two 
core components, dsRNA-binding protein DGCR8 and 
RNase III endonuclease Drosha [52, 54]. Microprocessor 
complex binds to the stem-loop structure of pri-miRNAs 
and cleaves the primary transcripts to release a hairpin-
shaped RNA molecule known as precursor miRNAs 
(pre-miRNAs) [52, 54]. The double-stranded pre-miR-
NAs are 70–100 nucleotides in length, and subsequently 
transported from nucleus to the cytoplasm by Exportin-5 
for further processing [52, 54]. Dicer, which is a RNase 
III endonuclease and responsible for the maturation of 
miRNAs in the cytoplasm, cleaves pre-miRNA to gener-
ate a double stranded miRNA duplex (miRNA–miRNA*) 
with 20–25 nucleotides in length [52, 54, 55]. The mature 
miRNA duplex is then recognized by the RNA induced 
silencing complex (RISC) containing Dicer and AGO2 
(argonaute RISC catalytic component 2). Usually, only 
one strand of miRNA duplex is preferentially chosen to 
be incorporated into the RISC to form miRNA-induced 
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silencing complex (miRISC) [55, 56]. The miRNA-loaded 
RISC binds to the target mRNAs and silences the gene 
expression through either degradation of mRNA or inhi-
bition of translation [55, 56].
MiRNA and thyroid hormone signaling
TH signaling has profound effects on many physiologic 
processes. The effectiveness of TH signaling relies on 
their capacity to tightly control the expression of target 
genes in time and space. The temporal and spatial activi-
ties of TH could be achieved through the regulation of 
the systemic and local levels of TH. The circulating TH 
levels are exquisitely regulated by a negative-feedback 
system that involves the hypothalamus–pituitary–thy-
roid axis, while the intracellular TH levels are modu-
lated by type 2 deiodinase, which is responsible for the 
conversion of prohormone T4 to bioactive T3. Recently, 
the miRNA field has grown tremendously and emerging 
evidence suggests that miRNAs not only confer signal-
ing robustness as amplifiers, balancers, or buffers but 
also play important roles in signaling crosstalk and coor-
dination as nodes of signaling networks. In 2007, Olson’s 
group published a research article in Science magazine 
that first linked the role of miRNA to TH signaling [57]. 
Soon afterward, the possible involvement of miRNAs 
in TH signaling networks has been indicated by several 
studies in a variety of model systems. In this review we 
summarize the major research progress with an emphasis 
on muscle-specific miRNAs (myomiRs), including miR-
208a/b, miR-499, miR-133, which play important roles in 
the regulation of the development, plasticity, and health 
of mammalian skeletal and cardiac muscles.
MiR‑208a
MiR-208a is located in the intron of α-MHC gene, which 
encodes a major cardiac contractile protein [58]. It was 
shown that cardiac-specific miR-208a was required for 
cardiomyocyte hypertrophy, fibrosis, and the expression 
of β-MHC in response to hypothyroidism [57]. Ablation 
of miR-208a attenuated cardiac hypertrophy in response 
to pressure overload and reduced β-MHC expression 
[57]. While cardiac overexpression of miR-208a was suf-
ficient to induce cardiac hypertrophy and cardiac con-
duction abnormalities [57]. Further study showed that 
miR-208a acted through repressing the TR co-regulator 
THRAP1 and myostatin, two negative regulators of mus-
cle growth and hypertrophy [57, 58]. Accordingly, inhi-
bition of miR-208a by antisense oligonucleotide delivery 
improved cardiac function, overall health, and survival 
during hypertension-induced heart failure [59].
It is well established that TH promotes α-MHC and 
inhibits β-MHC expression in the heart [16, 17]. Simi-
lar to the regulation of α-MHC by TH, the expression of 
miR-208a is also significantly blunted in the adult heart 
in response to hypothyroidism. To further explore the 
roles of miR-208a in the cardiac muscle, β-MHC expres-
sion was investigated in miR-208a knockout mice treated 
with propylthiouracil (PTU), which rendered the mice 
hypothyroid [58]. Interestingly, hypothyroidism could 
not induce β-MHC expression in the heart of miR-208a 
null mice pathway [58]. These findings provided direct 
evidence that miR-208a mediates TH action in heart.
MiR‑208b and miR‑499
Besides miR-208a, miR-208 family contains another two 
miRNAs, miR-208b and miR-499. They are encoded 
in different myosin genes, Myh7 (β-MHC) and Myh7b, 
respectively [60, 61]. These two intronic miRNAs have 
been shown to be involved in the control of muscle fiber 
type by activating slow and repressing fast myofiber gene 
programs [62]. Recently, it was reported that miR-208b 
and miR-499 are downstream targets of estrogen-related 
receptor γ (ERRγ), which mediates the effect of peroxi-
some proliferators-activated receptors β/δ and PPARα 
on energy metabolism and skeletal muscle fiber specific-
ity [63, 64]. As a result, activation of ERRγ could lead to 
an upregulation of miR-208b/miR-499 and subsequently 
increases type I muscle fiber proportion in skeletal mus-
cle [65]. As mentioned early, it is known that skeletal 
muscle is a target for TH and all members of the MyHC 
family respond to TH. Given that TH regulates myofiber 
type transition [66], it is not surprising to find that hypo-
thyroid state induces both Myh7/miR-208b and Myh7b/
miR-499 expression in skeletal muscle [62]. These find-
ings indicate that miR-208b and miR-499 might medi-
ate the effect of TH on myofiber type determination and 
energy metabolism.
MiR‑133
MiR-133 family is one of the most studied miRNA fami-
lies in skeletal muscle [67]. The enrichment of miR-133 
as well as miR-1 and miR-206 in heart and skeletal mus-
cle was first reported in 2004 [68], which was confirmed 
subsequently by several groups. Due to their tissue spe-
cific expression, these miRNAs are designated as canoni-
cal myomiRs, which have been extensively investigated 
[67, 69–72]. The miR-133 family (including miR-133a1, 
miR-133a and miR-133b) and miR-1 family (including 
miR-1-1, miR-1-2 and miR-206) are clustered on human 
chromosomes. Their sequences and expressions are evo-
lutionarily conserved across species [73].
Further study showed that miR-133a is highly expressed 
both in heart and in skeletal muscle, while miR-133b is 
specifically expressed in skeletal muscle [74]. Several 
studies confirmed that miR-133a played a regulatory role 
in the development of cardiac and skeletal muscle [72, 
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75, 76]. The most direct evidence came from miR-133a1 
and miR-133a2 knockout mouse models. In the heart, 
absence of miR-133a resulted in ectopic expression of 
smooth muscle genes and aberrant cardiomyocyte prolif-
eration due to elevated expression of SRF and cyclin D2, 
which were direct targets of miR-133a [72]. In the skeletal 
muscle, miR-133a knockout mice developed adult-onset 
centro nuclear myopathy in type II (fast-twitch) myofiber, 
accompanied by fast-to-slow myofiber transition, sug-
gesting an essential role of miR-133a in maintaining the 
structure, function, and myofiber types of skeletal muscle 
[77].
The link between TH and myomiRs was reported in 
flounder (Paralichthys olivaceus), which showed that 
miR-133a as well as miR-1 and miR-206a were TH-reg-
ulated miRNAs during larval development [78]. By using 
hypo- and hyperthyroid mouse models and TR isoform–
specific knockout mice, we demonstrated that miR-133a1 
transcription could be up-regulated directly by TH in a 
TR-dependent manner [38]. Our study also showed for 
the first that overexpression of miR-133a was able to 
promote slow-to-fast muscle switch by repressing TEA 
domain family member 1 (TEAD1), a key modulator of 
slow muscle gene [38]. Based on our in vivo and in vitro 
data, we proposed that miR-133a1 mediates the effect of 
TH on muscle fiber type specification [38]. Furthermore, 
our data showed that the negative regulation of MyHC-
I transcription by TH was indirect, suggesting that TH 
might not regulate MyHC-I transcription through a 
nTRE [38]. In addition, since miR-133a not only regu-
lates myofiber type switch but also plays a role in prolif-
eration, regeneration and remodeling, we speculated that 
TH signaling might have a variety of effects on muscle 
physiology and pathology through miR-133a1-mediated 
mechanisms.
Other miRNAs
Besides myomiRs, a few other miRNAs have been shown 
to serve as either regulators or components of TH signal-
ing. For example, miR-27a was demonstrated to modu-
late β-MHC gene expression in cardiomyocytes [79]. In 
cardiac hypertrophy and skeletal muscle atrophy, miR-
27a was strongly increased via Srf and Myf6 transacti-
vation [80, 81]. MiR-27a was upregulated during ES cell 
differentiation and heart development in mouse, imply-
ing a critical role of miR-27a in heart development [79]. 
Moreover, miR-27a overexpression strongly upregulated 
the β-MHC, but not α-MHC by targeting TRβ1 [79]. 
These studies highlighted the role of miR-27a in car-
diac pathophysiology as a regulator in the TH signaling 
pathway.
MiR-30a belongs to the miR-30 family, which is highly 
expressed in the heart [82]. Previous studies have shown 
that members of miR-30 family were downregulated in 
cardiomyocytes in response to ROS [83]. And they also 
play critical roles in calcium/calcineurin signaling in 
cardiomyocytes, which was demonstrated by deliver-
ing a miR-30 sponge to cardiomyocytes [84]. A recent 
study revealed that T3 could improve the recovery of 
post-ischemic cardiac performance via regulating the 
miR-30a/p53 axis [85]. In the ischemia/reperfusion (I/R) 
injury model, T3 could restore the expression level of 
miR-30a and then prevent the upregulation of p53, sug-
gesting an important role of miR-30a in mediating the 
cardioprotective effects of T3 [85].
Type 3 deiodinase (Dio3) is a TH-inactivating enzyme 
usually expressed at fetal stage, which regulates prolifera-
tion. In a myocardial infarction (MI) mouse model, Dio3 
is up-regulated in cardiomyocytes to create a local hypo-
thyroid condition to increase the regenerative capacity 
by initiating the fetal gene program. A group of miRNAs 
with altered expression levels were identified in this MI 
model and were predicted to be involved in the regula-
tion of stress response in cardiomyocytes [86]. Further 
study showed that Dio3 is a target of miR-214 [87]. 
Therefore, the upregulation of miR-214 observed in MI 
model might dampen the MI-induced upregulation of 
Dio3. The finding that miR-214 was negatively regulated 
by TH suggests that miR-214 and Dio3 form a negative 
feedback loop in cardiomyocytes. The interplay between 
miR-214 and Dio3 after MI provides a mechanism to 
protect the adult cardiomyocyte from the adverse effect 
of local TH deficiency [87].
It is known that hyperthyroidism induces cardiac 
hypertrophy and the Angiotensin type 1 receptor 
(AT1R) has been demonstrated to mediate part of this 
response. It was shown that T3 treatment increased 
AT1R mRNA and protein levels rapidly in cardiomyo-
cyte, which was accompanied with an increased of miR-
350 expression. Since AT1R is one of predicted target of 
miR-350, it is reasonable to make the assumption that 
miR-350 might be involved in TH-induced cardiomyo-
cyte hypertrophy [88]. On the other hand, two stud-
ies indicate that AT1R might contribute to the altered 
expression of cardiac miR-208a and miR-133 induced 
by hyperthyroidism [89, 90]. These findings provide new 
insights in the understanding of regulatory networks 
involved in the cardiac growth controlled by miRNAs 
and TH signaling.
Perspective
The effects of TH on heart and muscle have been well 
established. The emergence of the miRNA field has pro-
vided a unique avenue towards deeper understanding 
of the TH action in cardiac and skeletal muscle devel-
opment, regeneration and physiology. Recent studies 
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involving miRNAs and TH signaling in cardiac and skel-
etal muscle have shed light on the contributions of miR-
NAs to TH signaling (Fig. 1). These studies suggest that 
miRNAs have added an additional layer of complexity 
to the extensive TH effects in normal and disease states. 
Moreover, certain miRNAs have been proved to be the 
missing links to previously unrecognized mechanisms. 
So far, since most studies have tried to pinpoint the 
mechanism of miRNAs to their single downstream tar-
gets, systems biology approaches might be a better choice 
to explain miRNA activity under euthyroid, hyper and 
hypothyroid conditions. Despite the uncertainties, some 
of these miRNAs have the potential to eventually become 
heart or muscle disease biomarkers or even drug targets 
in future. Further investigations are required to address 
the relative contributions of miRNAs under physiological 
and pathological conditions and how a group of miRNAs 
are coordinated to integrate into the complex hierarchi-
cal regulatory network of TH.
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